project id: TCGA-PRAD; case submitter id: TCGA-J9-A8CK; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.92; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.14; rna integrity number: 7.3; age at index: 66; days to birth: -24285; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 24285; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 321.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 365; initial weight: 90.0; sample id: befc6582-0e80-4d57-9d8c-6f15f5e85e37; sample submitter id: TCGA-J9-A8CK-01A; portion id: 9cede30c-9844-419b-9922-4770b4df5d8d; portion submitter id: TCGA-J9-A8CK-01A-11; slide id: 395a1487-a9b1-4d0e-a349-7dc64622063e; slide submitter id: TCGA-J9-A8CK-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;